Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB088C Combined With MHB039A in Advanced Malignant Solid Tumors
NCT07126665Phase 2Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Sep 2025
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of MHB088C, MHB039A in advanced malignant solid tumor, sponsored by Minghui Pharmaceutical, Inc.. Started Sep 2025; status: recruiting.
02
Drugs
MHB088CMHB039A
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT07126665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126665.